The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus
2008

Vildagliptin for Type 2 Diabetes Management

publication Evidence: moderate

Author Information

Author(s): Chakraborti C.K.

Primary Institution: Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela, Orissa, India

Hypothesis

Vildagliptin, a DPP-4 inhibitor, can improve glycemic control in patients with type 2 diabetes mellitus.

Conclusion

Vildagliptin effectively reduces blood sugar levels and improves beta-cell function in type 2 diabetes patients without causing significant side effects.

Supporting Evidence

  • Vildagliptin reduces HbA(1)c levels in patients with poorly controlled blood sugar.
  • It improves insulin secretion and reduces glucagon levels in type 2 diabetes patients.
  • Clinical trials show vildagliptin is effective without causing significant weight gain or hypoglycemia.

Takeaway

Vildagliptin is a medicine that helps people with type 2 diabetes by making their bodies better at controlling blood sugar, and it doesn't usually cause bad side effects.

Methodology

The article reviews recent studies on vildagliptin's effects on blood sugar control and beta-cell function in type 2 diabetes patients.

Potential Biases

Potential risks include increased infections and interactions with other medications.

Limitations

Further long-term studies are needed to fully understand the benefits and risks of vildagliptin.

Participant Demographics

Patients with type 2 diabetes, including those inadequately controlled by metformin.

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.4103/0253-7613.40482

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication